Monitoring immune response to CMV after lung transplant
Treatments studied
Part of Ear, nose & throat clinical trials.
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a lung transplant, or a multi-organ transplant that included a lung, at NYU Langone Health
- You have had blood tests showing past exposure to CMV (CMV “R+”)
- You can understand the study and sign the consent form (or have a legally authorized helper if allowed)
- You are not receiving anti-thymocyte globulin (ATG) as an immune-suppressing medication at the time of the study
- You have not had perioperative desensitization treatment and you are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This study looks at how well your immune system fights CMV (a common virus) after you stop taking a preventive medicine called Letermovir. It aims to see if your immune recovery can predict later CMV infections.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This study looks at how CMV (a common virus) affects the immune system in people who get a kidney transplant or have CMV after transplant. It may help doctors understand and manage CMV better.
Hear when a new Lung Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.